To date, PD-L1 expression assessed by IHC remains the most widely used biomarker for predicting responses to ICIs in NSCLC, but its usefulness is tempered by technical and biological challenges [95]; its limitations include intra- and inter-tumor heterogeneity as well as the subjectivity inherent in pathologist interpretations [16]. This evidence concerns the gene CD274 and neoplasm.